India’s largest CDMO posts solid financial results, reinforcing its leadership in pharmaceutical manufacturing.
New Delhi, May 27, 2025 – Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter and fiscal year ending March 31, 2025. With a strong rebound in Q4, the company has laid the foundation for continued growth, innovation, and global expansion.
Robust Financial Performance in Q4 FY25
Akums posted ₹1,073 crore in revenue, reflecting an impressive 12.4% year-on-year (YoY) growth, with an EBITDA margin of 10.4%. Riding on this momentum, the company closed FY25 with a consolidated total income of ₹4,170 crore and an adjusted EBITDA margin of 12.3%, marking a seven basis point improvement from FY24.
Throughout the year, Akums maintained its focus on enhancing its product mix, building a differentiated research-driven portfolio, and expanding its global presence.
Strategic Expansion into European Markets
A key milestone in FY25 was Akums securing a €200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets. This deal significantly strengthens Akums’ global CDMO footprint, with commercial supplies set to commence in 2027.
To support its growing scale, Akums invested ₹272 crore in capital expenditure, expanding its production capacity to 49.6 billion units annually. This ensures readiness for large-scale domestic CDMO operations and global pharmaceutical market opportunities.
Innovation and R&D Leadership
Akums continues to lead in pharmaceutical innovation, allocating ₹130 crore—over 3% of its revenue—towards research and development (R&D). With 973 DCGI approvals and a portfolio of 4,000+ commercialized formulations across 60+ dosage forms, the company is reinforcing its commitment to therapeutic advancements.
Segment-Wise Performance
CDMO Business: Contributed ~78% to the group’s turnover, achieving an adjusted EBITDA margin of 14.1%.
- Domestic Branded Formulations: Recorded ~9% growth, while international branded formulations expanded by ~14%.
- Trade Generics & API Segment: Continued to face operational losses, but strategic measures are in place to drive profitability in FY26.
Future Outlook and Growth Strategy
Despite flat YoY revenue, mainly due to industry-wide muted volumes and price erosion in APIs, Akums remains committed to long-term growth. The company increased its R&D investment by 16% from FY24, strengthening its capabilities in complex formulations and innovative delivery formats.
Sanjeev Jain, Managing Director of Akums, reflected on the company’s evolution:
“As we celebrate the year Akums got listed, we also focus on a bold future. Our entry into Europe is a pivotal step in our global CDMO expansion. With capacity enhancements and differentiated offerings, Akums is on track to become a trusted name in global pharmaceutical manufacturing.”
Sandeep Jain, Managing Director, added:
“We take immense pride in closing FY25 on a positive note, despite industry volatility. Akums remains focused on operational discipline, innovation, and global ambition. Our new injectable facility is operational, our R&D engine is stronger than ever, and our portfolio continues to resonate with partners. We are excited about the future as we accelerate our transformation into a global pharmaceutical powerhouse.”
Key Financial Highlights (₹ Crore)
| Metric | Q4 FY25 | Q3 FY25 | Q4 FY24 | FY25 | FY24 |
|---|---|---|---|---|---|
| Revenue | 1,056 | 1,010 | 944 | 4,118 | 4,178 |
| Other Income | 18 | 15 | 10 | 52 | 34 |
| Total Income | 1,073 | 1,025 | 954 | 4,170 | 4,212 |
| COGS | 639 | 602 | 569 | 2,433 | 2,550 |
| Employee Cost | 184 | 176 | 164 | 716 | 647 |
| Other Expenses | 139 | 111 | 128 | 508 | 500 |
| Adj EBITDA | 111 | 136 | 98 | 513 | 515 |
| Adj EBITDA Margin | 10.4% | 13.3% | 10.3% | 12.3% | 12.2% |
| Depreciation | 40 | 45 | 34 | 153 | 126 |
| Finance Cost | 5 | 5 | 12 | 35 | 51 |
| Exceptional Item | -8 | -5 | 0 | -17 | 26 |
| Adj PAT | 44 | 66 | 46 | 234 | 220 |
| Adj PAT Margin | 4.1% | 6.5% | 4.8% | 5.6% | 5.2% |
Akums remains steadfast in its vision of innovation and global expansion, reinforcing its leadership in India’s pharmaceutical landscape while taking bold strides toward international markets.
